12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DNA IL-12: Phase II started

OncoSec said researchers at the University of California, San Francisco, began an open-label, U.S. Phase II trial to evaluate intratumorally injected DNA IL-12 followed by electroporation using OncoSec's OMS ElectroImmunotherapy applied to up...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >